Dana Farber Cancer Institute/Brigham and Women's Hospital is a clinical research site located in Boston, Massachusetts, United States 02215.
Crixeo Clinical Trials Trust Score: 94/100 (GOOD). This profile has not yet been claimed by the site owner.
Dana Farber Cancer Institute/Brigham and Women's Hospital has participated in 8 clinical trials with 2 currently active.
Therapeutic areas: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders.
Sponsors: Pierre Fabre Medicament, Nanobiotix, Orbus Therapeutics, Inc..
Is this your site? Claim your profile and control the information sponsors and patients see.
Browse all research sites in Massachusetts · View every site in Boston
Trust Score: 94/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Dana Farber Cancer Institute/Brigham and Women's Hospital has a Crixeo Trust Score of 94/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana Farber Cancer Institute/Brigham and Women's Hospital has 8 clinical trials on record, with 2 currently active. Their work covers Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders.
Dana Farber Cancer Institute/Brigham and Women's Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.